Literature DB >> 19074530

Dehydrogenation of the indoline-containing drug 4-chloro-N-(2-methyl-1-indolinyl)-3-sulfamoylbenzamide (indapamide) by CYP3A4: correlation with in silico predictions.

Hao Sun1, Chad Moore, Patrick M Dansette, Santosh Kumar, James R Halpert, Garold S Yost.   

Abstract

4-Chloro-N-(2-methyl-1-indolinyl)-3-sulfamoylbenzamide (indapamide), an indoline-containing diuretic drug, has recently been evaluated in a large Phase III clinical trial (ADVANCE) with a fixed-dose combination of an angiotensin-converting enzyme inhibitor, perindopril, and shown to significantly reduce the risks of major vascular toxicities in people with type 2 diabetes. The original metabolic studies of indapamide reported that the indoline functional group was aromatized to indole through a dehydrogenation pathway by cytochromes P450. However, the enzymatic efficiency of indapamide dehydrogenation was not elucidated. A consequence of indoline aromatization is that the product indoles might have dramatically different therapeutic potencies. Thus, studies that characterize dehydrogenation of the functional indoline of indapamide were needed. Here we identified several indapamide metabolic pathways in vitro with human liver microsomes and recombinant CYP3A4 that include the dehydrogenation of indapamide to its corresponding indole form, and also hydroxylation and epoxidation metabolites, as characterized by liquid chromatography/mass spectrometry. Indapamide dehydrogenation efficiency (V(max)/K(m)=204 min/mM) by CYP3A4 was approximately 10-fold greater than that of indoline dehydrogenation. In silico molecular docking of indapamide into two CYP3A4 crystal structures, to evaluate the active site parameters that control dehydrogenation, produced conflicting results about the interactions of Arg212 with indapamide in the active site. These conflicting theories were addressed by functional studies with a CYP3A4R212A mutant enzyme, which showed that Arg212 does not seem to facilitate positioning of indapamide for dehydrogenation. However, the metabolites of indapamide were precisely consistent with in silico predictions of binding orientations using three diverse computer methods to predict drug metabolism pathways.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19074530      PMCID: PMC2645476          DOI: 10.1124/dmd.108.022707

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  34 in total

Review 1.  The many roles of computation in drug discovery.

Authors:  William L Jorgensen
Journal:  Science       Date:  2004-03-19       Impact factor: 47.728

2.  Discovery of a novel binding trench in HIV integrase.

Authors:  Julie R Schames; Richard H Henchman; Jay S Siegel; Christoph A Sotriffer; Haihong Ni; J Andrew McCammon
Journal:  J Med Chem       Date:  2004-04-08       Impact factor: 7.446

Review 3.  Mass spectrometry in the analysis of glutathione conjugates.

Authors:  T A Baillie; M R Davis
Journal:  Biol Mass Spectrom       Date:  1993-06

4.  Detection and characterization of DNA adducts of 3-methylindole.

Authors:  K A Regal; G M Laws; C Yuan; G S Yost; G L Skiles
Journal:  Chem Res Toxicol       Date:  2001-08       Impact factor: 3.739

5.  Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone.

Authors:  Pamela A Williams; Jose Cosme; Dijana Matak Vinkovic; Alison Ward; Hayley C Angove; Philip J Day; Clemens Vonrhein; Ian J Tickle; Harren Jhoti
Journal:  Science       Date:  2004-07-15       Impact factor: 47.728

6.  Antioxidant activity of indapamide and its metabolite.

Authors:  A Tamura; T Sato; T Fujii
Journal:  Chem Pharm Bull (Tokyo)       Date:  1990-01       Impact factor: 1.645

7.  The disposition of 14C-indapamide in man.

Authors:  L J Klunk; S Ringel; E S Neiss
Journal:  J Clin Pharmacol       Date:  1983 Aug-Sep       Impact factor: 3.126

8.  Metabolic activation of a novel 3-substituted indole-containing TNF-alpha inhibitor: dehydrogenation and inactivation of CYP3A4.

Authors:  Hao Sun; Garold S Yost
Journal:  Chem Res Toxicol       Date:  2007-12-21       Impact factor: 3.739

9.  Indoline analogues of idazoxan: potent alpha 2-antagonists and alpha 1-agonists.

Authors:  G P Fagan; C B Chapleo; A C Lane; M Myers; A G Roach; C F Smith; M R Stillings; A P Welbourn
Journal:  J Med Chem       Date:  1988-05       Impact factor: 7.446

10.  The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-A resolution.

Authors:  Jason K Yano; Michael R Wester; Guillaume A Schoch; Keith J Griffin; C David Stout; Eric F Johnson
Journal:  J Biol Chem       Date:  2004-07-16       Impact factor: 5.157

View more
  9 in total

1.  Genetic polymorphisms of metabolic enzymes and the pharmacokinetics of indapamide in Taiwanese subjects.

Authors:  Teng-Hsu Wang; Cheng-Huei Hsiong; Hsin-Tien Ho; Tung-Yuan Shih; San-Jan Yen; Hui-Hung Wang; Jer-Yuarn Wu; Benjamin Pei-Chung Kuo; Yuan-Tsong Chen; Shung-Tai Ho; Oliver Yoa-Pu Hu
Journal:  AAPS J       Date:  2013-12-20       Impact factor: 4.009

2.  Two-dimensional NMR and all-atom molecular dynamics of cytochrome P450 CYP119 reveal hidden conformational substates.

Authors:  Jed N Lampe; Relly Brandman; Santhosh Sivaramakrishnan; Paul R Ortiz de Montellano
Journal:  J Biol Chem       Date:  2010-01-22       Impact factor: 5.157

Review 3.  Current Approaches for Investigating and Predicting Cytochrome P450 3A4-Ligand Interactions.

Authors:  Irina F Sevrioukova; Thomas L Poulos
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

4.  Improved cytochrome P450 3A4 molecular models accurately predict the Phe215 requirement for raloxifene dehydrogenation selectivity.

Authors:  Chad D Moore; Kiumars Shahrokh; Stephen F Sontum; Thomas E Cheatham; Garold S Yost
Journal:  Biochemistry       Date:  2010-10-19       Impact factor: 3.162

5.  Conformational dynamics of CYP3A4 demonstrate the important role of Arg212 coupled with the opening of ingress, egress and solvent channels to dehydrogenation of 4-hydroxy-tamoxifen.

Authors:  Kiumars Shahrokh; Thomas E Cheatham; Garold S Yost
Journal:  Biochim Biophys Acta       Date:  2012-06-04

Review 6.  The impact of SARS-CoV-2 treatment on the cardiovascular system: an updated review.

Authors:  Mohammed Ahmed Akkaif; Abubakar Sha'aban; Arturo Cesaro; Ammar Ali Saleh Jaber; Andrea Vergara; Ismaeel Yunusa; Abubakar Ibrahim Jatau; Mustapha Mohammed; G Saravana Govindasamy; Majed Ahmed Al-Mansoub; Muhamad Ali Sheikh Abdul Kader; Baharudin Ibrahim
Journal:  Inflammopharmacology       Date:  2022-06-14       Impact factor: 5.093

7.  Reversible dysphasia and statins.

Authors:  Gordon Robert Wyndham Davies
Journal:  J Korean Med Sci       Date:  2012-03-21       Impact factor: 2.153

Review 8.  Antihypertensive drugs metabolism: an update to pharmacokinetic profiles and computational approaches.

Authors:  Aikaterini Zisaki; Ljubisa Miskovic; Vassily Hatzimanikatis
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

Review 9.  Lopinavir-Ritonavir in SARS-CoV-2 Infection and Drug-Drug Interactions with Cardioactive Medications.

Authors:  Shubham Agarwal; Sanjeev Kumar Agarwal
Journal:  Cardiovasc Drugs Ther       Date:  2020-09-12       Impact factor: 3.727

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.